Abstract 11093: Comparing High-Flow Nasal Cannula Therapy and Conventional Oxygen Therapy in Adult Patients Post-Cardiac Surgery: A Systematic Review and Meta-Analysis
Abstract
Introduction/Background: Cardiac surgery frequently precipitates post-operative respiratory complications, increasing ICU admissions, morbidity, and mortality. Conventional Oxygen Therapy (COT) via nasal prongs, facemask, or venturi mask remains standard care but often fails to meet elevated post-operative oxygen demands. High-Flow Nasal Cannula (HFNC) therapy delivers heated, humidified oxygen at up to 60 L/min, reducing dead-space ventilation and work of breathing. However, the comparative efficacy and safety of HFNC versus COT in post-cardiac surgery patients remain inconsistent and inadequately defined across existing trials. Methods/Approach: This systematic review and meta-analysis adhered to PRISMA guidelines. A systematic search was conducted in PubMed, Embase, Scopus, and Cochrane Library from inception to May 2026, restricted to high-quality randomized controlled trials. Meta-analysis was performed using RevMan 5.4. Dichotomous outcomes were pooled as risk ratios (RRs) and continuous outcomes as mean differences (MDs) with 95% confidence intervals (CIs). A random-effects model was applied, and heterogeneity was quantified using the I 2 statistic. Sub Group Analysis was done on the basis of Risk Status and Treatment Strategy. Results: Eight RCTs were included. For the two primary outcomes, escalation of respiratory support was significantly lower with HFNC (RR 0.75 [95% CI: 0.58-0.97], p=0.03, I 2 =69%), while mortality showed no significant difference (RR 1.12 [95% CI: 0.54-2.33], p=0.75, I 2 =0%). Among secondary outcomes, intubation rate (RR 1.28, p=0.46), respiratory rate (MD –0.51, p=0.33), heart rate (MD 0.27, p=0.73), ICU LOS (MD 0.09, p=0.28), hospital LOS (MD –0.33, p=0.35), PaO 2 (MD 122.69, p=0.29), PaCO 2 (MD –2.31, p=0.07), FEV 1 (MD 0.05, p=0.40), FVC (MD 0.09, p=0.12), atrial fibrillation (RR 0.74, p=0.53), and delirium (RR 1.25, p=0.80) were all comparable between groups. Subgroup analysis by risk stratification revealed that escalation of respiratory support was significantly reduced with HFNC in low-risk patients (RR 0.62 [95% CI: 0.46-0.83], p=0.001), while no significant difference was observed in the high-risk subgroup (RR 0.82, p=0.11). Subgroup analysis by HFNC Treatment Strategy showed no significant difference in any outcome between prophylactic and therapeutic subgroups, with escalation of respiratory support trending lower in prophylactic use (RR 0.69, p=0.25) but reaching significance only in the overall pooled estimate. Conclusion(s): HFNC therapy significantly reduces escalation of respiratory support post-cardiac surgery compared to COT, though mortality and all secondary outcomes remained statistically comparable. High heterogeneity in certain outcomes warrants cautious interpretation. Larger multicenter RCTs are needed to establish HFNC as the definitive preferred post-operative oxygen strategy.